Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

AUGUST 29, 2022

Founder, CEO, President of Somai Pharmaceuticals. Top 200 Launch Event 7 September 2022. Song: Wicked Game by Chris Isaac. INTERVIEW 4. THE COMPLIANCE DISPENSARY. With AMY MCDOUGAL ATTORNEY AND FOUNDER OF CLEARESOURCES. Song: Gabriel’s Oboe by Ennio Morricone – Yo Yo Ma. Supplementary Information. CleaResources.com.

Pharmaceutical 52

Pharmaceutical Programs Compliance Compliance 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

SEPTEMBER 22, 2021

Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products. OCT is also responsible for the manufacture and supply of the compounds for development and commercialisation.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

SEPTEMBER 8, 2021

The platform was specifically designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation. For more information, please visit www.trutrace.co. About Applied DNA Sciences Inc.

Supply Chain 95

Supply Chain Pharmaceutical Seed-To-Sale Events 95

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials. About Marinus Pharmaceuticals. ET (12:00 p.m.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 5, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 2 Goates et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

NORML

MAY 26, 2020

Adverse events were mostly mild and resolved spontaneously. Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” The 1mg dose showed a significant pain decrease compared to the placebo.

Clinical Trials 250

Clinical Trials Chronic Pain Cannabinoids Patients 250

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 3, 2019

The event will serve as a platform for Icelandic consumers and entrepreneurs to learn about the many potential business opportunities and wellness benefits that hemp and hemp-derived cannabidiol (CBD) could bring to their country. . “Medical Marijuana, Inc. and throughout the world in the past 10 years. billion by 2020.

Events 40

Events Hemp Research and Development Supply Chain 40

Cannabis Life Network

JANUARY 5, 2021

Canopy Growth Corporation acquired a patented cannabis extraction technique that GW Pharmaceuticals allegedly infringed. Greenwich Biosciences is a US subsidiary of GW Pharmaceuticals […]. So, two giant players in Canada’s commercial cannabis are now in a head to head legal battle.

Extraction 112

Extraction Pharmaceutical Cannabis Legalization 112

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 82

Pharmaceutical Clinical Trials Research and Development Events 82

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

SEPTEMBER 3, 2021

Flora Lab is acknowledged for its quality procedures which are now in line with global pharmaceutical companies after it receives GMP certification from INVIMA to manufacture cosmetics products. Has more than 18 domestic clients and sells branded products along with white-label products. Forward-looking statements are only predictions.

Supply Chain 93

Supply Chain Wellness and Beauty Pharmaceutical Events 93

Cannabis Law Report

JULY 2, 2021

We apply our entirely subjective bong score to each event. CannaVerde Pharma is a vertically integrated medical cannabis company with core operations in Colombia, focused on delivering low-cost, pharmaceutical grade, EU-GMP compliant cannabis-based products to consumers and medical patients in Latin America and Europe. BONG SCORE.

Sleep 105

Sleep Pharmaceutical THC Extraction 105

Cannabis Law Report

NOVEMBER 23, 2019

for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.

Pharmaceutical 45

Pharmaceutical Research and Development Cultivation Environment 45

Cannabis Law Report

JULY 21, 2021

” About Tryp Therapeutics: Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. San Diego, California–(Newsfile Corp.

Clinical Trials 105

Clinical Trials Chronic Pain Research and Development Treatment 105

Cannabis Law Report

AUGUST 25, 2021

The purchase and amalgamation of Consolidated Craft Brands was announced on March 19, 2021 bringing CPG and pharmaceutical manufacturing experience and Health Canada licenses for R&D. Actual results and future events could differ materially from those anticipated in such forward-looking statements. www.rapid-dose.com.

Events 111

Events Pharmaceutical Research and Development Business 111

Cannabis Law Report

SEPTEMBER 10, 2021

Xpira Pharmaceuticals Inc. It intends to enable and empower society at large to make better, more mindful decisions about psychedelics and their intersection with healthcare, medicine, and personal growth. Dimensions Health Centres Inc.

Research and Development 102

Research and Development Microdosing Pharmaceutical Education 102

Cannabis Law Report

JULY 24, 2021

With full government approval through Health Canada for exclusive access to a full cGMP-certified pharmaceutical manufacturing facility, Mydecine continues to advance the clinical progress in its 4 leading novel compounds, MYCO-001 through 004 with the ability to import or export, cultivate, extract or isolate, and analyze active mushroom compounds.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

FloridaMarijuana.net

AUGUST 15, 2018

Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

Cannabis Law Report

AUGUST 16, 2021

The Acquisition provides Sproutly with fully automated, pharmaceutical grade manufacturing equipment to produce high quality cannabis confectionaries, such as gummies and chocolates, at a lower cost and at a larger scale to meet the projected demands for the Canadian market. (the “Acquisition” ).

Events 105

Events Edibles Pharmaceutical Business 105

Cannabis Law Report

AUGUST 19, 2021

The industrial hemp market is being driven by the rising application of the fibre in various industries, including food and beverage, personal care, pharmaceutical and textiles, among others. 15 Industry Events and Developments. Key Topics Covered: 1 Preface. 2 Report Coverage – Key Segmentation and Scope. 3 Report Description.

Hemp 98

Hemp Research and Development Pharmaceutical Data 98

Cannabis Law Report

JULY 26, 2021

From recreational to pharmaceutical applications, we see amazing potential for novel applications of the device.”. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Events 105

Events Cannabinoids Advocacy Cannabis 105

Cannabis Law Report

NOVEMBER 17, 2021

The National Pharmaceutical Regulatory agency (NPRA) approved Sativex in 2014 for patients experiencing muscle spasms and spasticity from multiple sclerosis. In a press event, public health minister, Anutin Charnvirakul said that the ministry would promote medical cannabis to help people access treatment safely and within the law.

Research and Development 111

Research and Development Patients Treatment Pharmaceutical 111

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52